Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [
CT perfusion
Dynamic positron emission tomography (PET)
Kinetic analysis
Non-small cell lung cancer (NSCLC)
Pathologic complete response (pCR)
Stereotactic ablative radiation therapy (SABR)
[18F]FDG
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
13 Jan 2021
13 Jan 2021
Historique:
received:
11
06
2020
accepted:
08
01
2021
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
22
9
2021
Statut:
epublish
Résumé
Stereotactic ablative radiation therapy (SABR) is effective in treating inoperable stage I non-small cell lung cancer (NSCLC), but imaging assessment of response after SABR is difficult. This prospective study aimed to develop a predictive model for true pathologic complete response (pCR) to SABR using imaging-based biomarkers from dynamic [ Twenty-six patients with early-stage NSCLC treated with SABR followed by surgical resection were included, as a pre-specified secondary analysis of a larger study. Dynamic [ RPA identified three response groups based on tumour blood volume before SABR (BV In this study, we developed a predictive model based on dynamic [ MISSILE-NSCLC, NCT02136355 (ClinicalTrials.gov). Registered May 8, 2014, https://clinicaltrials.gov/ct2/show/NCT02136355.
Sections du résumé
BACKGROUND
BACKGROUND
Stereotactic ablative radiation therapy (SABR) is effective in treating inoperable stage I non-small cell lung cancer (NSCLC), but imaging assessment of response after SABR is difficult. This prospective study aimed to develop a predictive model for true pathologic complete response (pCR) to SABR using imaging-based biomarkers from dynamic [
METHODS
METHODS
Twenty-six patients with early-stage NSCLC treated with SABR followed by surgical resection were included, as a pre-specified secondary analysis of a larger study. Dynamic [
RESULTS
RESULTS
RPA identified three response groups based on tumour blood volume before SABR (BV
CONCLUSIONS
CONCLUSIONS
In this study, we developed a predictive model based on dynamic [
TRIAL REGISTRATION
BACKGROUND
MISSILE-NSCLC, NCT02136355 (ClinicalTrials.gov). Registered May 8, 2014, https://clinicaltrials.gov/ct2/show/NCT02136355.
Identifiants
pubmed: 33441162
doi: 10.1186/s13014-021-01747-z
pii: 10.1186/s13014-021-01747-z
pmc: PMC7805034
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Banques de données
ClinicalTrials.gov
['NCT02136355']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11Subventions
Organisme : Canada Foundation for Innovation
ID : 11358
Organisme : Ontario Institute for Cancer Research
ID : Clinician-Scientist Grant
Références
Cancer Treat Rev. 2008 Dec;34(8):719-27
pubmed: 18657910
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1057-65
pubmed: 17905527
J Nucl Med. 2012 Apr;53(4):521-9
pubmed: 22414637
BMC Cancer. 2012 Jul 23;12:305
pubmed: 22823994
Anticancer Res. 2001 Nov-Dec;21(6B):4285-300
pubmed: 11908683
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):974-8
pubmed: 20932655
Eur J Radiol. 2011 Jul;79(1):147-54
pubmed: 19954913
Lung Cancer. 2007 May;56(2):229-34
pubmed: 17353064
Breast Cancer Res Treat. 2009 Sep;117(2):325-31
pubmed: 19152025
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
Psychol Methods. 2009 Dec;14(4):323-48
pubmed: 19968396
J Med Imaging Radiat Oncol. 2019 Feb;63(1):94-101
pubmed: 30281918
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):685-92
pubmed: 18164849
JAMA Oncol. 2019 May 1;5(5):681-688
pubmed: 30789648